PreludeDx™ Enters into Agreement with Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims for its Novel DCIS Test, DCISionRT®

Agreement with MCCP Provides Access to DCISionRT to Over 150,000 Providers LAGUNA HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it has entered into a...

Click to view original post